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Abstract: Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE 
has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and 
II are inherited as an autosomal dominant disorder. The generation of an HAE attack is caused by the depletion and/or consumption of 
C1-inhibitor manifested as subcutaneous or submucosal edema of the upper airway, face, extremities, or gastrointestinal tract mediated 
by bradykinin. Attacks can be severe and potentially life-threatening, particularly with laryngeal involvement and treatment of acute 
attacks in the United States has been severely limited. In December 2009 the FDA approved ecallantide for the treatment of acute HAE 
attacks. Ecallantide is a small recombinant protein acting as a potent, specific and reversible inhibitor of plasma kallikrein which binds 
to plasma kallikrein blocking its binding site, directly inhibiting the conversion of high molecular weight kininogen to bradykinin. 
Administered subcutaneously, ecallantide was demonstrated in two clinical trials, EDEMA3 and EDEMA4, to decrease the length and 
severity of acute HAE attacks. Although there is a small risk for anaphylaxis, which limits home administration, ecallantide is a novel, 
safe, effective and alternative treatment for acute HAE attacks.
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Introduction
Hereditary angioedema (HAE) is a clinical disorder 
characterized by a deficiency of C1 esterase inhibi-
tor  (C1-INH)  that  results  from  mutations  of  the 
C1-INH gene located on chromosome 11.1,2 It was 
first recognized in 1963 that C1-INH was deficient 
in the plasma of patients with HAE.3 Inherited as an 
autosomal dominant disorder, it is unique among the 
inherited deficiencies of the complement system as 
HAE Types I and II are occur with equal frequency 
among  both  men  and  women.  Low  levels  of  both 
C1-INH  proteins  distinguish  Type  I  HAE,  which 
accounts for approximately 80% to 85% of all HAE 
cases. Type II HAE, which occurs in 15% to 20% of 
patients, results from decreased functional activity of 
the C1-INH gene, but with normal C1- INH levels.4,5
Recently, a new subtype of HAE, Type III, has 
been described in the literature. Type III is charac-
terized  by  an  X-linked  dominant  inheritance  and 
initially observed exclusively in women and is asso-
ciated with normal levels and function of C1-INH.6 
Most cases appear to be estrogen induced;7 however, 
more recently males have been identified that appear 
to have type III HAE, but with normal levels of C4, 
C1-INH-A and C1-INH-F.
Generation of HAE attacks are caused by the deple-
tion and/or consumption of C1 inhibitor. The role of 
C1-INH in regulation of the contact system activation, 
via inactivation of plasma kallikrein and factor XIIa, 
was discovered during the 1970s and 1980s.8 Via inac-
tivation of C1r and C1s, C1-INH is the primary regu-
lator of the classic complement pathway activation.9 
The low plasma concentration of functionally active 
C1-INH permits overactivation of the kallikrein-kinin 
system, the classical complement pathway, the fibrin-
olytic system and the coagulation system, with release 
of  vasoactive  peptides  among  which  bradykinin  is 
considered  to  be  most  important.10–12 Bradykinin is 
released by cleavage of kininogen by kallikrein and it 
is capable of inducing edema as a result of its effects 
on vasodilation and microvessel permeability.13,14
The exact prevalence of HAE is not known, but it 
has been estimated to range from 1:10,000 to 1:150,000 
in the general population. This suggests that there are 
2000 to 30,000 affected patients in the United States 
(US).14 Patients with HAE typically begin to swell in 
childhood and often experience increase symptoms 
beginning about the time of puberty.15
Clinically,  HAE  is  characterized  by  episodic 
recurrent episodes of subcutaneous and sub-mucosal 
angioedema. Swelling affects the hands and feet but 
also involves the genitalia, trunk, face, upper airways, 
larynx, and gastrointestinal tract.16 The disease is char-
acterized by swelling, which is not associated with 
urticaria, that does not respond to antihistamines, cor-
ticosteroids or epinephrine. Swelling during attacks 
usually  subsides  spontaneously  in  72  hours.17  In 
one study, abdominal attacks were reported in more 
than 93% of patients and composed almost 50% of 
all  angioedema  attacks.18  However,  skin  swellings 
appear to be the most frequent symptoms of HAE.19
A positive family history of angioedema is present 
in most patients, although up to 25% of patients have 
negative family histories with a de novo C1 inhibi-
tor mutations.18 Thus, the absence of a family history 
in the presence of typical symptoms should not be 
a deterrent from making the diagnosis. Even within 
families with the same genetic aberration symptoms 
vary considerably and it is not unusual for one family 
member to have severe recurrent attacks and another 
to be relatively free of symptoms.
History of Treatment for Acute  
HAe Attacks
HAE attacks can be variable in both frequency and 
severity. In the United States, the treatment for acute 
HAE attacks has been severely limited until recently. 
Therapies have included fresh frozen plasma (FFP), 
17α-alkylated androgens, and antifibrinolytic agents. 
All of which have their inherent safety and side effect 
profiles.20–22 (Table 1) In October of 2009, the FDA 
approval  of  C1-INH  replacement  (Berinert®;  CSL 
Behring, Melbourne, Australia) greatly improved the 
treatment options available for the treatment of acute 
attacks. More recently, in December, 2009 the United 
States Food and Drug Association (FDA) approval 
of ecallantide (Kalbitor® [previously, DX-88]; Dyax, 
Cambridge, MA) for acute attacks in patients 16 years 
of age has allowed for even greater treatment options 
of this rare, but potentially life threatening disorder.23 
Ecallantide has not been studied for prevention of 
HAE attacks as prophylactic therapy.
pharmacology and pharmacokinetics
Ecallantide is a small recombinant protein (7054 Da) 
synthesized in the yeast Pichia pastoris and acts as Ecallantide for treatment of HAE
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Half-life Route of 
treatment
FDA status
FFP (fresh frozen 
plasma)
Blood product Replaces C1 
esterase inhibitor
Long IV Used, but not approved for 
the treatment of acute HAE 
attacks
Berinert® Plasma concentrate C1 inhibitor 24–46.5 h IV FDA approved for the 
treatment of acute attacks
Ecallantide Recombinant protein Kallikrein inhibitor 1–4 h SC FDA approved for the 
treatment of acute HAE 
attacks
Abbreviations: HAE, hereditary angioedema; IV, intravenous; SC, subcutaneous.
a potent, specific, and reversible inhibitor of plasma 
kallikrein. Ecallantide binds to plasma kallikrein and 
blocks its binding site, directly inhibiting the conver-
sion of high molecular weight kininogen (HMWK) to 
bradykinin.24–27
Ecallantide  is  eliminated  in  the  urine  and  after 
administration of a single 30 mg subcutaneous dose, 
a mean (±standard deviation) maximum plasma con-
centration of 586 ± 106 ng/mL was observed approx-
imately 2 to 3 hours post-dose in healthy subjects. 
The mean area under the concentration-time curve 
was 3017 ± 402 ng*hr/mL with a mean elimination 
half-life of 2.0 ± 0.5 hours. Plasma clearance was 
153 ± 20 mL/min and the volume of distribution was 
26.4 ± 7.8 L. Body weight, age, and gender were not 
found  to  affect  ecallantide  exposure  significantly. 
There is no pharmacokinetic data available in patients 
with hepatic or renal impairment.27
Dosing strategy
Each single use vial contains ecallantide at a concen-
tration of 10 mg/mL with a recommended dose of 
30 mg, administered subcutaneously in three 10 mg 
(1 mL) injections. A repeat dose (30 mg) can be given 
if the attack persists and may be administered within 
a 24 hour period. Ecallantide is usually administered 
in the abdomen, thigh, or upper arm with each injec-
tion site separated by at least five centimeters and 
away from the anatomical site of attack.
Use in special populations
Ecallantide is labeled as pregnancy category C as it was 
noted to cause developmental toxicity in rats in doses 
approximately 8 times (based on mg/kg) the maximum 
recommended human dose. Therefore, it is suggested 
to  use  ecallantide  with  caution    during    pregnancy. 
  Additionally,  it  is  unknown  whether  ecallantide  is 
excreted in human milk and caution should be also 
exercised when administered to nursing women.
Clinical trials did not include sufficient numbers 
of subjects aged 65 and over to determine response 
in elderly patients. Currently approved for patients 
16 years of age and older, the safety and effectiveness 
in pediatric patients has yet to be established.
safety and Tolerability
In 255 patients between the ages of 10 and 78 years 
with  HAE  treated  with  either  intravenous  or  sub-
cutaneous ecallantide, the most adverse effect was 
headache (16.1%). Additional side effects included 
nausea (12.9%), fatigue (11.8%), diarrhea (10.6%), 
upper  respiratory  tract  infection  (8.2%),  injection 
site reactions (7.4%), nasopharyngitis (5.9%), vom-
iting (5.5%), pruritus (5.1%), upper abdominal pain 
(5.1%), and pyrexia (4.7%).27 As noted, the above 
data is combined from all patients treated with ecal-
lantide either intravenously in the EDEMA1® trial28 
or  via  subcutaneous  administration  documented  in 
the EDEMA3® and EDEMA4® trials.29,30 As ecallan-
tide is a recombinant product, it is free of potential 
human or animal contaminants.31
During clinical trials, hypersensitivity reactions, 
including anaphylaxis, occurred in patients receiving 
ecallantide. In the aforementioned 255 HAE patients 
treated with intravenous or subcutaneous, 10 patients 
(3.9%) experienced anaphylaxis. In the subgroup of 
patients (n = 187) receiving subcutaneous adminis-
tration, 5 patients (2.7%) experienced anaphylaxis. 
The  symptoms  associated  with  these  anaphylactic 
reactions  included  chest  discomfort,  flushing,  pha-
ryngeal edema, pruritus, rhinorrhea, sneezing, nasal 
congestion, throat irritation, urticaria, wheezing, and Lunn and Banta
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hypotension and all occurred within the first hour after 
dosing. Thus, Kalbitor®, has a black box warning for 
this hypersensitivity risk. Other adverse reactions sug-
gestive of hypersensitivity reactions included pruritus 
(5.1%), rash (3.1%), and urticaria (2.0%). Therefore, 
it is recommended that patients should be observed 
for an appropriate period of time after administra-
tion, and the medication should only be used in the 
presence of healthcare workers who are trained in the 
treatment of anaphylaxis. Prior to prescribing, physi-
cians are obligated to discuss this potential adverse 
reaction extensively with their patients.
A  few  patients  treated  with  ecallantide  devel-
oped antibodies to the medication. Overall, 7.4% of 
patients seroconverted to anti-ecallantide antibodies 
with  rates  increasing  over  time.  Neutralizing  anti-
bodies to ecallantide in vitro were noted in 4.7% of 
patients. Additionally, anti-P. pastoris IgE antibodies 
were also detected.27
FDA Approval and clinical studies
The safety and efficacy of ecallantide was evaluated 
in 2 randomized, double-blind, placebo-controlled tri-
als (EDEMA4® and EDEMA3®) in 168 patients with 
HAE.29,30 Patients having an acute attack of heredi-
tary angioedema, at any anatomic location, with at 
least  1  moderate  or  severe  symptom,  were  treated 
with 30 mg subcutaneous ecallantide or placebo. As 
patients could participate in both trials, there were a 
total of 143 unique patients between the two trials. In 
both trials, the effects of ecallantide were evaluated 
using the Mean Symptom Complex Severity (MSCS) 
score and the Treatment Outcome Score (TOS). These 
measures evaluated the severity of attack symptoms at 
all anatomical locations (MSCS score) and response 
to therapy (TOS) (Tables 2 and 3). A decrease in the 
MSCS score reflected an improvement in   symptoms 
and  TOS  is  a  measure  of  symptom  response  to 
  treatment. During the EDEMA4® and EDEMA3® tri-
als, safety was also assessed documenting headache, 
nausea, and diarrhea were the most common adverse 
effects (Table 4).
EDEMA4®  was  a  randomized,  double-blind, 
  placebo-controlled  trial  in  which  96  patients  were 
randomized to receive ecallantide 30 mg subcutane-
ous or placebo for acute attacks of HAE. The primary 
endpoint  was  the  change  from  baseline  in  MSCS 
score at 4 hours, and the TOS at 4 hours was a key 
secondary  endpoint.  Results  showed  that  patients 
treated  with  ecallantide  demonstrated  a  greater 
decrease from baseline in the MSCS than placebo and 
a greater TOS than patients with placebo (Table 2).
EDEMA3®  was  a  randomized,  double-blind, 
  placebo-controlled trials in which 72 patients were 
randomized to receive ecallantide or placebo for acute 
attacks of HAE. The primary endpoint was the TOS at 
4 hours, and the key secondary efficacy endpoint was 
the change from baseline in MSCS at 4 hours. As in 
EDEMA4®, patients treated with 30 mg of ecallantide 
demonstrated a greater decrease from baseline in the 
MSCS than placebo and a greater TOS than patients 
treated with placebo (Table 3).
Based on EDEMA4 and EDEMA3 trials,   Kalbitor® 
(ecallantide)  was  FDA  approved  for  treatment  of 
acute HAE attacks on December 1, 2009 in patients 
16 years of age and older.
Limitations in clinical Application
As noted above, there were a few side effects noted 
including nausea, fatigue, diarrhea, upper respiratory 
Table 2. Change in MSCS score and TOS at 4 hours in 
EDEMA4.
ecallantide placebo
Change in MSCS score at 4 hours
  Number 47 42
  Mean -0.8 ± 0.6 -0.4 ± 0.8
  P-value 0.010
TOS at 4 hours
  Number 47 42
  Mean 53.4 ± 49.7 8.1 ± 63.2
 P -value 0.003
Abbreviations:  MSCS,  Mean  Symptom  Complex  Severity;  TOS, 
Treatment Outcome Score.
Table 3. Change in MSCS score and TOS at 4 hours in 
EDEMA3.
ecallantide placebo
Change in MSCS score at 4 hours
  Number 36 36
  Mean -0.88 ± 1.11 -0.51 ± 0.68
  P-value 0.01
TOS at 4 hours
  Number 36 36
  Mean 46.8 ± 59.3 21.3 ± 69.0
  P-value 0.004
Abbreviations:  MSCS,  Mean  Symptom  Complex  Severity;  TOS, 
Treatment Outcome Score.Ecallantide for treatment of HAE
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Table 4. Adverse reactions occurring at $3% and higher 
than placebo in 2 placebo in EDEMA3® and EDEMA4® 
in patients treated for acute HAE attacks.




Headache 8 (8%) 6 (7%)
Nausea 5 (5%) 1 (1%)
Diarrhea 4 (4%) 3 (4%)
Pyrexia 4 (4%) 0
Injections site reaction 3 (3%) 1 (1%)
Pharyngitis 3 (3%) 0
tract infection, injection site reactions, nasopharyn-
gitis, vomiting, pruritus, upper abdominal pain, and 
pyrexia. None of which should preclude the clinician 
from offering this treatment option to their heredi-
tary angioedema patients as the benefits appear to 
outweigh the risks. However, the risk of anaphylaxis 
could be a limiting factor in clinical use as it has to be 
administered in a clinical setting supervised by health 
care professionals. It has been well documented that 
treatment of HAE attacks early decrease the severity 
and length of attacks. Ideally, treatment of an attack 
would occur in any setting at the onset of symptoms 
and at the patient’s convenience. This is currently not 
an option with ecallantide and has the potential to 
delay timely treatment.
conclusion
The recommended dose for the treatment of acute HAE 
attacks is 30 mg administered subcutaneously with a 
maximum of 2 doses (60 mg) in a 24 hour period. 
The current wholesale price (2010) for Kalbitor® is 
$9,540.00  per  30  mg  treatment.  ($3,180.00/10  mg 
vial). Therefore, cost of treatment can be a barrier to 
treatment based on insurance coverage. Additionally, 
there remains controversy on when to initiate chronic 
replacement therapy in individuals with HAE versus 
treatment isolated to acute attacks. Cost is a factor, 
but  chronic  treatment  for  HAE  with  C1-Inhibitor 
replacement may lead to more expense. The cost is 
dependent on the frequency of attacks and ultimately 
the number of doses used.
There  have  been  major  advances  in  the  treat-
ment options available for acute HAE attacks in the 
United States over the past year. The hope is that 
those advances correlate with an increase in the qual-
ity of life for patients with HAE. Safety remains a 
  concern with a small risk of anaphylaxis, in addition 
to the lack of availability for home administration and 
  ecallantide’s  potential  for  immunogenicity.  Unique 
aspects for ecallantide include subcutaneous adminis-
tration which is a significant advantage for individu-
als with poor peripheral venous access. In conclusion, 
ecallantide remains a novel, safe, and effective treat-
ment for acute HAE attacks.
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